TechCrunch’s Disrupt SF (September 5-7) will be one for the record books, with twice the attendees and twice the programming sessions compared to past Disrupts, which means we can tackle emerging, super-exciting categories like biotech with both great speakers and a section of Start Up Alley devoted to biotech startups. (Pssst biotech founders… there is still time to win a free TC Top Picks exhibition spot in Startup Alley complete with three Founder Passes to take in all of Disrupt SF. Apply here.)
Today we’re delighted to announce a panel of three top biotech investors, who will share their perspectives on key trends in biotech and where they are looking to make their next investments.
Laura Deming is the founder and partner in the $26 million Longevity Fund, a venture capital firm focused on biological research to reduce or reverse the effects of aging. Deming was accepted to MIT at age 14, but later dropped out to accept the $100,000 Thiel Fellowship and start a venture capital firm. Deming believes that before long we’ll retire the idea of growing old. So far, Deming has backed Unity Biotechnology, Precision Biosciences, Metacrine, Navitor and Alexo Therapeutics.
Nina Kjellson is a general partner at Canaan Partners, where she invests in biopharma and digital health companies that serve unmet needs. Kjellson serves as a mentor to Blueprint Health and Springboard Life Sciences and on the boards of Essential Access Health and the Oliver Wyman Health Innovation Center. She holds a B.A. in human biology from Stanford University, and her recent investments include Annum Health, Dauntless, PACT Pharma, Tizona Therapeutics and Vineti.
Arvind Gupta is a general partner at SOSV, a $150 million early-stage venture capital fund, where he founded IndieBio, a biotech accelerator based in San Francisco. IndieBio focuses on startups that will either touch a billion people or create a billion in value. Arvind received his B.S. in genetic engineering from UCSB and has invested in Memphis Meats, Synthex, Medel.AI and Catalog.
And that’s not all — we have a lot more coming in health and biotech, plus 23andMe’s Ann Wojcicki, whom we have already announced.